REDUCE-IT trial participants allocated to icosapent ethyl had minimal changes in biomarkers associated with atherosclerotic disease, a new sub-study has shown. In contrast, there were increases in biomarker levels in those allocated to the mineral oil used as placebo in the trial. At baseline, median levels of each biomarker were similar in REDUCE-IT participants randomly […]
Elevated remnant cholesterol aids heart disease prediction
Very elevated (>75th percentile) non-fasting REM-C or non-fasting TG deserve further evaluation as a potentially valuable modifier of atherosclerotic cardiovascular disease risk. Replication of current findings could potentially improve the care of patients at risk of ischaemic events.
NICE predicts hundreds of thousands to benefit from new icosapent ethyl guidance
New guidance about the use of icosapent ethyl (Vazkepa) for reducing cardiovascular (CV) risk, issued by the National Institute for Health and Care Excellence (NICE), is expected to benefit around 425,000 people in England treated on the country’s free National Health Service (NHS). NICE has recommended icosapent ethyl as an option for reducing the risk of CV events (eg. myocardial infarction and stroke) in adults.
